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Summary Small cell lung cancer (SCLC) is treated primarily with combination chemotherapy. Despite high
initial response rates, most patients eventually die with drug resistant disease. In some tumours, resistance to
multiple chemotherapeutic agents is attributed to overexpression of P-glycoprotein (P-gp). However, this does
not appear to be a frequent occurrence in drug resistant SCLC. Increased levels of glutathione (GSH) and
related enzymes may play a role in resistance to alkylating agents as well as natural product drugs. We
measured levels of GSH, glutathione S-transferase (GST), glutathione reductase (GSH Red), glutathione
peroxidase (GSH Px), and y-glutamyl transpeptidase (y-GT) in a panel of 20 SCLC cell lines. Most of these
lines were established from patients treated at this centre. Each cell line had a characteristic and reproducible
profile of GSH and related enzyme levels. Immunoblot analysis indicated that the predominant GST in the cell
lines was the anionic isoenzyme. The relative sensitivity of each of these cell lines to 16 different
chemotherapeutic agents was measured using a modified MTT assay. Spearman rank correlation analysis was
used to determine the relationships between the relative chemosensitivity of these cell lines and the levels of
GSH and related enzymes. The number of positive correlations was no greater than expected by chance alone.
Furthermore, there was no correlation with the treatment history of the patients from whom the cell lines were
derived. These data suggest that alterations in glutathione metabolism do not play a major role in resistance to
chemotherapeutic agents in these human SCLC cell lines.
Small cell lung cancer (SCLC) comprises about 25% of
bronchogenic carcinomas. This tumour has many clinical and
pathological features which distinguish it from the other
major types of lung cancer, collectively referred to as non
small cell lung cancer (NSCLC) (Cohen & Matthews, 1978).
Chemotherapy is the primary modality of therapy in SCLC.
Treatment usually consists of combination chemotherapy,
including agents such as cyclophosphamide, doxorubicin, vin-
cristine, VP-16, and either cisplatin or carboplatin. Response
rates of up to 90% can be achieved with combination
chemotherapy, and a small proportion of patients are prob-
ably cured (Seifter & Ihde, 1988).
Despite impressive initial responses to chemotherapy, the
majority of patients eventually succumb to their disease, and
the major reason for treatment failure is the acquisition of
resistance to multiple chemotherapeutic agents (multidrug
resistance). The most frequently described alteration in mul-
tidrug resistant cells of various tumour types is the overex-
pression of a plasma membrane protein, termed P-glyco-
protein (P-gp), which serves to actively export drugs from
cells (Bradley et al., 1988). Although P-glycoprotein overex-
pression has been detected in some multidrug resistant SCLC
lines (Reeve et al., 1989; Minato et al., 1990), other multi-
drug resistant SCLC cell lines do not overexpress this drug
efflux pump (Mirski et al., 1987; Cole et al., 1991; de Jong et
al., 1990; Nygren et al., 1991). Furthermore, studies of large
numbers of SCLC cell lines and clinical samples indicate that
P-gp overexpression does not occur frequently in this disease
(Lai et al., 1989; Noonan et al., 1990; Milroy et al., 1992).
Consequently, there has been interest in other potential
mechanisms of multidrug resistance in SCLC.
Increasing attention has focused on the role of glutathione
and glutathione-related enzymes in drug resistance.
Glutathione (GSH) is a tripeptide thiol which plays a critical
role in protection of cells from the toxic effects of radiation,
oxygen radicals, endogenous toxins, and xenobiotics. GSH
and its associated enzymes have been implicated in resistance
to alkylating agents (Ahmad, 1987; Buller et al., 1987; Wax-
man, 1990) and platinum compounds (Teicher et al., 1987;
Hospers et al., 1988; Meijer et al., 1990; Saburi et al., 1989).
As well, they may play a role in resistance to natural product
drugs which are part of the multidrug resistance phenotype
(Batist et al., 1986; Kramer et al., 1988), although this has
been questioned (Yusa et al., 1988).
In SCLC, the evidence implicating alterations in GSH
metabolism in drug resistance is inconclusive. Changes in
levels of GSH and related enzymes have been found in
certain SCLC cell lines which have undergone in vitro selec-
tion for drug resistance (Cole et al., 1990; Meijer et al.,
1990). However, it is unclear whether these differences are
functionally related to the drug resistance phenotype. Others
have studied these enzymes in large collections of lung cancer
cell lines (Morstyn et al., 1984; Carmichael et al., 1988c).
While differences between NSCLC and SCLC lines were
found, the results for lines derived from untreated patients
were similar to those from treated patients (Carmichael et al.,
1988c). Furthermore, no relationship was found between
levels of glutathione and related enzymes and radiation sens-
tivity profiles of lung cancer cell lines (Morstyn et al., 1984).
Thus, while many groups have examined GSH and related
enzymes in small cell and other lung cancers, the involvement
of these cellular detoxification mechanisms in drug resistance
in these tumours remains uncertain.
The purpose of the present investigation was to examine
the relationship between the levels of GSH and related
enzymes, and the drug sensitivity profiles of a large panel of
SCLC cell lines, as well as the treatment histories of the
patients from whom the cell lines were derived. For these
studies, a collection of 20 SCLC cell lines was used. These
cell lines do not overexpress P-gp as detected using the
polymerase chain reaction (Campling, Cole and Gerlach,
unpublished results). The levels of GSH, and associated
enzymes GST, GSH Px, GSH Red and 'y-GT were measured
in these lines. Multivariate statistical analysis was employed
to correlate the drug sensitivity profiles of the cell lines, and
the treatment history of the patients from whom the lines
were derived, with their levels of GSH and related enzymes.
Materials and methods
Chemicals and reagents
NADPH, oxidised and reduced GSH, GSH Red, DTNB,
CDNB, rat liver and human placental GST, cumene hyd-
roperoxide, BSA, goat anti-rabbit IgG alkaline phosphatase
conjugate, hydrocortisone, insulin, transferrin, estradiol,
sodium selenite, and '-GT kit were purchased from Sigma
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Chemical Co. (St. Louis, MO). Normal goat serum (NGS)
was obtained from Cedarlane (Hornby, Ontario), and FBS
from Gibco (Burlington, Ontario). Antibodies, raised in rab-
bits, to GST isoenzymes x, 1i and a (Bioprep, Dublin, Ire-
land) were provided by Drs K. Tew and M. Clapper, Fox
Chase Cancer Center, Philadelphia, PA. The antibody to
GST was raised to the human isoenzyme, and the
antibodies to GST ft and a were raised to rat isoenzymes.
According to the manufacturer, these antibodies are specific
for the individual GST isoenzymes, and they detect both rat
and human forms of the enzymes.
Cell lines
The properties of the 20 SCLC cell lines used in these studies
are summarised in Table I. The conditions for establishing
and maintaining the cell lines have been described (Campling
et al., 1992). Twelve of the cell lines were established in this
laboratory. The histologic features of the majority of these
lines have been described (Campling et al., 1992). Four of the
lines (LD-T, MO-A, OS-A and SV-E) have not been
previously described. Cell lines LD-T, MO-A, and OS-A are
classical SCLC cell lines, and SV-E is an atypical SCLC. Cell
lines NCI-H69, NCI-H128, and NCI-H209 were obtained
from Dr J.D. Minna, NCI-Navy Medical Oncology Branch,
National Institutes of Health, Bethesda, Maryland. H69AR
is a doxorubicin-selected multidrug resistant variant of NCI-
H69 which does not overexpress P-gp (Mirski et al., 1987).
Cell line Mar was obtained from Prof. A. Neville, Ludwig
Institute for Cancer Research, London, UK. (Ibson et al.,
1987). SHP-77 was established by Fisher and Paulson,
(1978), and was obtained from Dr J. Fogh, Sloan Kettering
Institute for Cancer Research, New York. Cell lines RG-1
and MM-1 were obtained from Dr W.E.C. Bradley, Institute
du Cancer de Montreal, and were characterised in this
laboratory (Campling et al., 1992).
All of the lines were grown in RPMI 1640 medium supp-
lemented with hydrocortisone (10nM), insulin (10fgml-'),
transferrin (10 f.g ml- 1), estradiol (10 nM), and selenium
(30 nM) (HITES medium) and 2.5% FBS. They were main-
tained in 5% CO2 in a humidified atmosphere at 37°C. The
treatment that the patients had received at the time that the
cell lines were established is indicated in Table I. The re-
sponse to further chemotherapy (if given and known) is also
shown in this table.
Fresh SCLC tumour samples andearly passage cell lines
Fresh tumour samples were obtained from two patients.
Sample No. 1 was pleural fluid from a patient who presented
with extensive stage SCLC. He was treated initially with oral
VP-16, and had a partial response. He then developed pro-
gressive disease despite further chemotherapy. A
thoracentesis was performed to relieve dyspnea. The patient
died shortly afterwards. Sample No. 2 was pericardial fluid
from a patient who presented with extensive stage disease,
and was treated initially with combination chemotherapy,
consisting of cylcophosphamide, doxorubicin and vincristine,
alternating with VP-16 and cisplatin. He had a partial re-
sponse, but then developed progressive disease while on
therapy. A pericardiocentesis was done to relieve cardiac
tamponade. The patient improved temporarily, but then pro-
gressed on oral VP-16, and died.
For both of these fresh tumour samples, the fluid was
centrifuged, and the cells were separated on a Ficoll-
Hypaque gradient. The cells were put into tissue culture in
HITES medium with 2.5% FBS and 50plml m' gentamycin.
Assays for GSH, GST, GSH Px and GSH Red were per-
formed as outlined below. For patient sample No. 1, the
assays were done on the day after the sample was received,
and for sample No. 2, the assays were performed after the
sample had been cultured for 5 days. Cytocentrifuge prepara-
tions were done to determine the proportion of tumour cells
in each of the specimens.
Both of these tumour samples continued to grow in cul-
ture, and the results of GSH and related enzymes were
repeated after several months in culture, and compared to the
results on the original samples.
Drug sensitivity testing
A modified MTT assay, as described previously (Campling et
al., 1991), was used to quantitate the response of the 20 cell
lines to 16 different chemotherapeutic agents. The drugs
Table I SCLC cell lines
Cellline Source Prior treatment Rxandresponse Obtainedfrom (reference)
NCI-H69 Pleural effusion CMC-VAP UK J.D. Minna(Carney etal., 1985; Carmichael
etal., 1988b)
H69AR Multidrug resistant variant of Selected in vitro in NA S.P.C. Cole(Mirski etal., 1987) NCI-H69 doxorubicin
NCI-H128 Pleural effusion CMC-VAP UK J.D. Minna(Carney etal., 1985; Carmichael
etal., 1988b)
NCI-H209 Bone marrow UT UK J.D. Minna(Carney etal., 1985; Carmichael
etal., 1988b)
Mar Primary tumour S UK A. Neville(Ibson etal., 1987) SHP-77 Primary tumour S UT-PD J. Fogh (Fisher & Paulson, 1978) AD-A Needle aspirate ofsubcutaneous lesion CA,VP/CP,RT M-PD Thislaboratory (Campling etal., 1991) BK-T Primary tumour S CAV-NA Thislaboratory(Camplingetal., 1991) LG-T Lymph node UT CAV,VP/CP-CR Thislaboratory(Camplingetal., 1991) HG-E Pleural effusion UT UT-PD Thislaboratory(Campling etal., 1991) JO-E Pleural effusion CAV,VP/CP,RT UT-PD Thislaboratory(Camplingetal., 1991) WL-E Pleuraleffusion VP/CP,CAV UT-PD Thislaboratory(Camplingetal., 1991) JN-M Bone marrow UT CAV,VP/Carb-PD Thislaboratory(Camplingetal., 1991) SH-A Needle aspirate oflymph node CAV,VP/CP CAV,VP/CP-PR Thislaboratory(Camplingetal., 1991) RG-1 Pericardial effusion CAV,VP/CP UK-PD W.E.C. Bradley(Campling etal., 1991) MM-1 Pleural effusion CAV,VP/CP UK-PD W.E.C. Bradley(Camplingetal., 1991) LD-T Primary tumour S CAV,VP/CP-NA Thislaboratory (unpublished) MO-A Needle aspirate oflymph node CAV,VP/CP CAV,VP/CP-CR Thislaboratory (unpublished) OS-A Needle aspirate ofsubcutaneous lesion CAV,VP/CP UT-PD Thislaboratory(unpublished) SV-E Pleural effusion CAV VP/CP-PD Thislaboratory(unpublished)
The source oftumourcells from which thecell line was derived is indicated. Prior treatment indicates thetherapy that thepatient had received at the time that thecell line wasestablished: UT -untreated; S -surgery; RT -radiotherapy; CMC-VAP -cyclophosphamide, methotrexate, CCNU, vincristine, doxorubicin, procarbazine; CAV -cyclosphosphamide, doxorubicin, vincristine; VP/CP-VP-16,cisplatin; carb -carboplatin; M -
mitoxantrone.
Rxandresponse indicates the treatment that thepatient received after the time that thecell line wasestablished. The response to that treatment is also indicated: CR -complete response; PR -partial response; PD -progressive disease; NA -not assessable; UK -unknown.GLUTATHIONE IN SMALL CELL LUNG CANCER 329
tested included doxorubicin, amsacrine, carboplatin, cis-
platin, 4-hydroperoxy-cyclophosphamide, daunomycin,
epirubicin, melphalan, menogaril, mitomycin-C, mitoxant-
rone, nitrogen mustard, vinblastine, vincristine, VM-26, and
VP-16. The response of the individual cell lines to each of the
drugs tested was expressed as the area under the dose re-
sponse curve (AUC) (Lam et al., 1990).
Assaysfor glutathione and related enzymes
Cells from logarithmically growing cultures were harvested
and used for these assays. Protein determinations were per-
formed by the Lowry method as modified by Peterson (1977)
for all assays except for the y-GT assay, for which a one
reagent method was used (BioRad, Richmond, CA).
The levels of total reduced and oxidised GSH were
measured using a modification of the method of Tietze,
(1969), with DTNB as a substrate. The assay was performed
in microtiter plates, and the rate of colour formation at
410 nm was recorded. Results are expressed as .tg GSH mg'
protein.
GST, GSH Red, and GSH Px assays were performed on
cell cytosols prepared by sonicating 1-2 x 107 cells for three
15 s pulses with a 30 s pause between pulses, followed by
centrifugation at 100,000 g at 4'C for 20 min.
Total GST was measured using the method of Habig et al.
(1974), with CDNB as a substrate. The rate of conjugation of
CDNB with GSH was recorded at 340 nm. Results are ex-
pressed as nmol of CDNB reduced min-' mg'- protein.
GSH Px levels were measured by the method of Paglia and
Valentine (1967) as modified by Reddy (1981) using hy-
drogen peroxide and cumene hydroperoxide as substrates.
The assay follows the rate of loss of NADPH at 340 nm, and
results were expressed as nmol NADPH consumed min-.'
mg-' protein.
GSH Red was measured using the method of Carlberg and
Mannervik (1975), and results expressed as nmol NADPH
consumed min-' mg- protein.
'-GT activity was measured on solubilised membrane
preparations using a kit based on the method of Szasz
(1969). Absorbance was followed at 405 nm, and results ex-
pressed as nmoles p-nitroaniline producedmin-'mg-1 pro-
tein.
Immunodetection ofGST isoenzymes
Cytosolic preparations that had been assayed for GST
activity were frozen at - 20°C and used later for
immunodetection of GST 7r, a, and ft. Cytosolic proteins
(50 gg) were separated by electrophoresis on a 15% polyac-
rylamide gel (Laemmli, 1970). Purified human placental GST
(No. isoenzyme) and rat liver GST (x and 1i isoenzymes) were
included as controls. Proteins were transferred overnight to
Immobilon-P (Millipore, Mississauga, Ontario) at 100 mA
according to the memnod of Towbin et al. (1979). The blots
were then blocked with 5% skim milk in TBS for 1 h.
Antibodies to GST x, A, and a were diluted 1:5000 in
TBS. The membranes were incubated with either pooled
anti-GST-a and I, or anti GST-t in 3% BSA/5% NGS/TBS
for 1 h. The blots were incubated with alkaline phosphatase-
conjugated goat anti-rabbit secondary antibody (1:8000) in
3% BSA/5% NGS/TBS. Immunodetection was performed
using nitroblue tetrazolium and bromochloroindolyl phos-
phate as substrates (Cole et al., 1990).
Spearman correlation analysis
Spearman rank correlation analysis (Armitage & Berry, 1987)
was used to determine the relationship between the results of
each of the GSH and related enzyme assays with the drug
sensitivity results for the 16 different drugs. Cell line H69AR
was omitted from this analysis, since it was the only cell line
which had undergone in vitro selection for drug resistance.
Thus, a total of 19 observations were included in the analysis
(i.e. one AUC value for each of 19 cell lines - for some of the
cell lines the AUC was the average of multiple observations,
and for other cell lines it was a single measurement. The
P-value indicating the significance of each individual correla-
tion was also calculated (SAS Institute Inc., 1990). Scatter
plots (96 ofthem) were produced to visualise the relationship
between the variables. The Bonferroni multiple comparison
method with the Fisher z-transformation of the correlation
coefficients was applied to determine significant correlations
at the overall 0.05 level of significance (Morrison, 1976).
Correlation with treatment status
To correlate the results of GSH and related enzymes with the
treatment status of the patients from whom the cell lines
were derived, the cell lines were classified as 'treated' or
'untreated' with chemotherapy, on the basis of the clinical
information in Table I. The mean values for cell lines from
treated patients were compared to the mean values for cell
lines from untreated patients. Because of the skewed distribu-
tion of the data, the Wilcoxan rank sum (or Mann-Whitney
U) test was used to make this comparison (Armitage &
Berry, 1987; SAS Institute Inc., 1990).
Results
Drug sensitivity testing
The results of chemosensitivity testing for 16 of the cell lines
(NCI-H69, H69AR, NCI-H128, NCI-H209, Mar, SHP-77,
AD-A, BK-T, LG-T, HG-E, JO-E, WL-E, JN-M, SH-A,
RG-1, and MM-1) have been published previously (Campling
et al., 1991). The results with the remaining four cell lines
(LD-T, MO-A, OS-A, and SV-E) are summarised in Table
II. The results are expressed as area under the dose response
curve, calculated using the trapezoidal method as described
(Lam et al., 1990). It can be seen that these four cell lines are
quite similar in terms of response to the various drugs. The
previously reported 16 cell lines represent a wider range of
drug responsiveness.
Glutathione and related enzyme levels
The levels of GSH, GST, GSH Px, GSH Red and y-GT in
the 20 cell lines are shown in Table III. It can be seen that
each of the cell lines had a characteristic and reproducible
profile of GSH and associated enzyme levels. The GSH levels
ranged from 0.35 to 7.69Ag mg-' protein in the SCLC lines.
GST levels varied from 4.83 to 248 nmol min- mg-' protein.
GSH Px ranged from 0 to 49.3 nmol min 'mg-' protein
Table II Chemosensitivity results
Cell line
Drug LD-T MO-A OS-A SV-E
Doxorubicin 37.3 29.4 34.0 67.8
Amsacrine 9.8 11.1 18.8 19.0
Carboplatin 54.0 80.1 98.2 89.2
Cisplatin 43.0 31.6 67.9 55.6
4H-cyclophosphamide 57.9 52.9 61.9 88.3
Daunomycin 9.3 5.8 10.7 13.8
Epirubicin 23.7 10.8 28.7 29.8
Melphalan 28.4 32.5 62.2 63.2
Menogaril 10.4 14.2 16.2 13.8
Mitomycin C 29.8 20.8 37.7 30.9
Mitoxantrone 19.9 17.6 22.7 40.5
Nitrogen mustard 26.3 17.9 45.3 33.1
Vinblastine 48.9 35.9 60.3 47.4
Vincristine 65.8 67.5 74.7 95.1
VM-26 31.2 28.6 32.4 13.6
VP-16 80.2 58.6 73.1 70.5
The chemosensitivity results for 16 of the cell have been published
(Campling et al., 1991). The results for the remaining four cell lines
are presented here. Results are expressed as area under the dose
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with H202 and from 1.47 to 47.7 nmol min-' mg-' protein
with cumene hydroperoxide as a substrate. GSH Red levels
varied from 13.0 to 115 nmol min-1mg-' protein, and Ty-GT
ranged from 0 to 9.1 nmol min-' mg-' protein.
Spearman correlation analysis
The results of the correlation analysis are shown in Table IV.
The six GSH related measurements were correlated with
sensitivities to 16 different drugs, giving a total of 96 different
pairs of correlations. Table IV shows that there were four
correlation coefficients with P values <0.05. This is no
greater than would be expected by chance alone. The highest
correlation coefficient was between response to 4-
hydroperoxy-cyclophosphamide and GSH levels (r = 0.64,
P = 0.004). Other correlations with P values <0.05 included
a negative correlation with m-amsacrine response and GST
levels (r = 0.49, P = 0.03), and a positive correlation between
Table III GSH and related enzymes in SCLC cell lines
GSH Px
Cell line GSH GST H202 Cumene GSH Red y-GT
NCI-H69 3.89 ± 1.53 163 ± 18 7.1 ± 2.7 10.0 ± 2.8 34.5 + 2.6 0.39 ± 0.20
H69AR 0.35 0.28 185 11 10.0 5.8 9.98 2.9 37.7 11.7 5.07 1.09
NCI-H128 0.96 ± 0.32 19.8 ± 3.4 14.8 ± 4.9 14.7 ± 4.7 52.4 ± 8.8 0.37 ± .24
HCI-H209 4.28 ± 2.25 170 ± 25 16.7 ± 4.7 22.0 ± 2.3 40.6 ± 1.9 0.12 ± .12
Mar 1.28 ± 0.56 89.2 22.6 5.0 2.3 5.2 3.9 44.9 9.6 0.68 ± .02
SHP-77 5.52 3.02 92.1 ±21.5 28.9 15.7 34.4 10.5 115 11 9.10 ± 1.96
AD-A 2.46 + 0.79 42.9 ± 8.7 5.88 + 1.17 6.83 i .85 57.2 ± 18 0.036 ± .042
BK-T 3.16 ± 1.33 9.79 ± 2.48 18.4 ± 4.8 19.8 ± 12.9 44.5 ± 7.2 0.02 ± .03
LG-T 1.57 ± 0.63 248 ± 59 16.6 7.4 8.9 1.6 17.6 0.8 0.23 ± .25
HG-E 2.22±0.97 191 35 0±0 1.47 1.41 21.1 5.0 0.18±.15
JO-E 2.18 ± 1.75 11.1 ± 4.8 11.0 ± 3.6 8.03 ± 5.57 56.9 ± 5.4 0.31 ± .14
WL-E 3.06 1.66 172 22 49.3 ± 1.8 37.8 ± 11.3 13.0 1.7 0.24±.12
JN-M 1.49 ± 0.77 104 ± 24 12.7 ± 6.9 13.4 ± 3.7 37.8 ± 3.5 0.36 ± .37
SH-A 2.17 ± 0.75 39.6 ± 29.6 10.4 ± 2.4 7.3 ± 7.5 37.3 ± 5.0 0.18 ± .30
RG-1 2.97 ± 1.59 5.66 ± 3.71 17.5 ± 6.2 17.3 ± 3.4 15.0 ± 2.6 0.19 ± .08
MM-1 3.43 2.09 71.7 4.7 19.2 4.7 19.1 ±3.6 21.0 4.2 0 0
LD-T 4.81 ± 2.53 64.4 3.7 5.7 2.2 5.05 ± 1.80 50.0 4.0 0.28 ± .28
MO-A 3.21 ± 1.62 115 ± 29 9.57 ± 2.43 7.69 ± 2.84 32.3 ± 7.0 0.56 ± .49
OS-A 7.69 ± 2.04 4.83 ± .71 24.0 ± 2.1 18.6 ± 7.0 35.7 ± 4.7 0.29 ± .04
SV-E 7.18±3.04 241±35 36.1±9.1 47.7±21.4 108±5.0 7.55±1.11
Levels ofGSH, GST, GSH Px, GSH Red and y-GT were determined for 20 cell lines. Assays
were performed at least three times on each cell line, and standard deviations are indicated. The
units for GSH are lg ml- protein. All enzyme levels are expressed as nmol min-'mg-'
protein.
Table IV Spearman correlation analysis
GSH Px
Drug GSH GST H202 Cumene GSH Red y-GT
Doxorubicin 0.12 0.17 0.09 0.03 -0.21 0.02
(0.62) (0.48) (0.70) (0.91) (0.38) (0.92)
Amsacrine -0.01 -0.49 0.60 0.50 -0.07 -0.09
(0.95) (0.03) (0.006) (0.03) (0.78) (0.71)
Carboplatin 0.03 -0.22 0.14 -0.01 -0.15 0.24
(0.91) (0.36) (0.56) (0.96) (0.54) (0.32)
Cisplatin 0.17 -0.24 0.26 0.07 -0.02 0.14
(0.51) (0.34) (0.30) (0.78) (0.95) (0.58)
4H-Cyclophosphamide 0.64 -0.05 0.25 0.10 0.03 0.31
(0.004) (0.84) (0.32) (0.69) (0.92) (0.20)
Daunomycin -0.25 -0.26 0.24 0.03 -0.13 -0.14
(0.31) (0.28) (0.32) (0.91) (0.61) (0.57)
Epirubicin 0.16 0.11 0.20 0.12 0.11 0.21
(0.52) (0.64) (0.40) (0.64) (0.65) (0.40)
Melphalan 0.24 0.03 0.24 0.07 -0.04 0.31
(0.32) (0.90) (0.32) (0.76) (0.88) (0.19)
Menogaril 0.03 -0.10 0.27 0.05 -0.22 0.23
(0.91) (0.69) (0.26) (0.83) (0.37) (0.34)
Mitomycin C 0.09 -0.29 0.26 0.05 0.07 0.09
(0.71) (0.23) (0.28) (0.84) (0.77) (0.71)
Mitoxantrone -0.12 0.07 0.22 0.12 -0.18 0.01
(0.63) (0.76) (0.35) (0.64) (0.47) (0.98)
Nitrogen mustard 0.24 0.00 0.01 -0.12 -0.03 0.11
(0.32) (0.99) (0.97) (0.62) (0.90) (0.66)
Vinblastine 0.08 -0.07 0.06 -0.09 -0.14 0.22
(0.76) (0.76) (0.79) (0.70) (0.58) (0.37)
Vincristine -0.14 0.03 -0.08 -0.24 -0.08 0.06
(0.57) (0.89) (0.75) (0.32) (0.75) (0.79)
VM-26 -0.09 -0.40 0.07 -0.20 -0.24 -0.14
(0.73) (0.10) (0.79) (0.42) (0.34) (0.59)
VP-16 0.20 -0.12 -0.10 -0.24 -0.04 -0.13
(0.41) (0.61) (0.69) (0.33) (0.87) (0.60)
The levels of GSH and related enzymes were correlated with the drug sensitivity of the cell lines to
16 different drugs. The correlation coefficients are indicated. The statistical significance of these
correlations (Pvalues) is shown in brackets below the correlation coefficients. Correlation coefficients
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m-amsacrine response and levels of GSH Px, using hydrogen
peroxide (r = 0.60, P = 0.006) and cumene hydroperoxide
(r = 0.50, P = 0.03) as substrates. Scatter plots corresponding
to the 96 correlations made in this study did not show any
apparent non-linear relationships between the variables.
With a total of 96 correlations to be considered in this
study, correlation coefficients exceeding 0.66 are considered
significant using the Bonferroni method. The conclusions of
the Bonferroni simultaneous tests lead to a more cautious
assessment of the strengths of the relationships between the
assays and the drug sensitivity results. However, the Bonfer-
roni approach may be excessively conservative, and thus the
P value for each individual correlation is also given in Table
IV.
We have also correlated levels of these various enzymes
with themselves (data not shown). The total GSH levels
correlated with GSH Px activity measured with both H202
(r = 0.49, P = 0.02) and cumene hydroperoxide (r = 0.42,
P = 0.05) as substrates. In addition, GSH Red correlated
with y-GT levels (r = 0.49, P = 0.02). The GSH Px levels
using the two different substrates, H202 and cumene hyd-
roperoxide, were highly correlated (r = 0.90, P = 0.0001).
Correlation with treatment status
The GSH and associated enzyme levels in the cell lines
derived from treated patients were compared to those derived
from untreated patients. There were no significant differences
between the two groups of cell lines (data not shown).
Fresh SCLC tumour samples and early passage cell lines
Both of the fresh tumour samples consisted of more than
90% tumour cells. The results of assays for GSH and related
enzymes are shown in Table V. It can be seen that the values
obtained are in the same range as for the SCLC cell
lines.
The assays were repeated after the samples had been main-
tained in vitro for several months. It can be seen from Table
V that the values for many of the assays were not stable after
prolonged tissue culture. For example, the initial GST level
for sample No. 1 was 83.5 nmol min- mg'- protein, but
after several months, this level had declined to
20.7 nmol min-' mg-l protein. On the other hand, for sam-
ple No. 2, the level of GSH Red increased from 7.74 nmol
min-'mg-' protein initially, to 25.6 nmol min' mg-' pro-
tein after in vitro culture.
Immunodetection ofGST isoenzymes
Immunoblots using antibodies to three subclasses of GST (a,
fi and n) were performed on 15 cell lines. The remaining lines
had levels of GST that were too low for detection on
immunoblots (cell lines OS-A, JO-E and RG-1), or
insufficient amounts of cell lysate available at the time (cell
lines Mar, SH-A and MO-A).
The results are shown in Figure 1. The antibody to GST a
detected the GST isoenzyme(s) present in human placenta,
but not rat liver, and the antibodies to GST a andfm detected
GST isoenzymes in rat liver, but not human placenta. It can
be seen that the a isoenzyme of GST was present in these 15
Table V GSH and related enzymes in fresh tumour samples and
early passage cell lines
GSH Px
cell lines. The a and tL isoenzymes were not detectable in any
of these unpurified samples (data not shown).
In addition to the SCLC lines, a cell line BH-E is shown in
Figure 1. This line was derived from a recurrent pleural
effusion in a patient who was originally diagnosed and
treated as SCLC. However, the histology on the cell line
derived from this patient showed adenocarcinoma. This cell
line was not included in the correlation analysis.
Discussion
Despite the fact that many groups have studied the role of
alterations in glutathione metabolism in drug resistant SCLC,
the importance of these mechanisms of resistance in this
tumour has not been clarified. In this study, very few
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significant correlations were found between levels of GSH or
its related enzymes and drug sensitivity of these human
SCLC cell lines. Furthermore, there were no differences in
levels in cell lines derived from treated patients compared to
those derived from untreated patients. Thus, our results pro-
vide support for the idea that GSH related detoxification
mechanisms do not play a major role in drug resistance in
SCLC.
In this report, we have examined larger numbers of SCLC
lines than previously studied by other investigators. The drug
sensitivity profiles of these lines have been extensively charac-
terised, and they display a wide range of drug sensitivity
(Campling et al., 1991). Furthermore, the treatment histories
of the patients from whom these lines were obtained are well
documented, and they are known to represent a spectrum of
clinically drug sensitive and drug resistant tumours. Thus,
our results may reflect the clinical situation.
The GST's have been intensively investigated as potential
mediators of drug resistance. These enzymes catalyse the
conjugation of GSH to electrophilic substances, thus render-
ing them more water soluble. The observation by Batist et al.
(1986) that a multidrug resistant human breast cancer cell
line overexpressed the isoenzyme of GST led to increased
interest in this isoenzyme as a potential marker of drug
resistance. Subsequently, numerous groups have found in-
creased expression of GST in cell lines and clinical samples
which are resistant to alkylating agents (Buller et al., 1987;
Gupta et al., 1989; Armstrong et al., 1992), nitrosoureas
(Ali-Osman et al., 1990), platinum compounds (Teicher et al.,
1987; Nakagawa et al., 1988; Saburi et al., 1989), and natural
product drugs (Whelan et al., 1989; Peters & Roelofs, 1992;
Singh et al., 1989). However, the functional role of GST in
drug resistance has been questioned, since many multidrug
resistant cell lines do not overexpress this isoenzyme (Yusa et
al., 1988). Furthermore, a multidrug resistant variant of the
breast cancer cell line, MCF-7, which overexpresses GST x,
retained elevated levels of this enzyme when it reverted to a
drug sensitive phenotype (Yusa et al., 1988).
One of the most direct approaches to resolving the ques-
tion of whether increased expression of GST alone confers
drug resistance is to transfect the gene into drug sensitive
cells, and examine the drug response of the transfectants. A
number of groups have taken this approach, with variable
results. Some have found no changes in drug sensitivity of
the transfectants, despite increased levels of GST activity
(Moscow et al., 1989; Fairchild et al., 1990). Others have
found GST transfected cells to be resistant to doxorubicin,
whereas the effect on sensitivity to alkylating agents has been
variable (Nakagawa et al., 1990; Puchalsky & Fahl, 1990;
Black et al., 1989). In general, the levels of resistance
detected have been low.
One of the largest studies of the role of GSH metabolism
as a determinant of drug sensitivity in lung cancer was that
of Carmichael et al. (1988c), which examined 30 different
SCLC and NSCLC cell lines. Significant differences were
found between the results for the SCLC compared to the
NSCLC lines. They speculated that these alterations could
account for the differences in drug sensitivity between these
two tumour types. However, a reanalysis of this data by
Hosking et al. (1990) showed no correlation between GSH
levels and doxorubicin response in these cell lines. Further-
more, no differences were found between results for cell lines
from previously untreated and previously treated patients.
Our results are in accordance with these findings.
We found that the only detectable GST in our cell lines
was the isoenzyme. Others have found that GST is the
predominant transferase in normal lung, and is overexpressed
in lung tumours (Howie et al., 1990; Awasthi et al., 1987;
Carmichael et al., 1988a).
Although our data do not show significant correlations
between drug sensitivity and alterations in GSH metabolism,
it is possible that we may have underestimated the impor-
tance of these metabolic pathways. In some experimental
systems, increased capacity for glutathione synthesis in re-
sponse to cytotoxic drugs has been demonstrated (Ahmad et
al., 1987; Lee et al., 1989; Meijer et al., 1990). Such changes
may not be detected by static measurements of levels of GSH
and associated enzymes, as carried out in this study.
It is also possible that changes in subcellular localisation of
GSH and related enzymes may be involved in mediating drug
resistance in SCLC. For example, Lutzky et al. (1989) have
detected altered subcellular distribution of GSH and GST in
a multidrug resistant variant of the leukaemia cell line,
HL60, using a fluorescent probe, monochlorobimane, which
is conjugated to GSH by GST. Since our measurements were
done on whole cell lysates, we would not have detected such
alterations.
Another concern is that the GSH and related enzyme
levels, and/or the drug sensitivity profiles of the cell lines may
not reflect the levels from the original tumour samples from
which the lines were derived. In a previous report we found
that the drug sensitivity of cell lines from untreated patients
was greater than that of lines from treated patients, although
the results were statistically significant for only two of the
drugs (Campling et al., 1991). Some of these cell lines have
been in continuous culture for several years. We have not
seen any major change in drug sensitivity profiles of these
lines over the years. However, it is possible that GSH and
related enzyme levels may have altered. In the case of one
cell line (NCI-H69), we found that the GST level increased
over a two year period (Cole et al., 1991).
For this reason, we examined fresh tumour samples and
early passage cell lines from two patients with SCLC. Both of
these patients had developed recurrent disease while on
chemotherapy, and were considered clinically drug resistant.
The results from the early passage cell lines indicate that
some of the measurements were not stable after in vitro
culture. This raises the important concern that some features
of human tumour cell lines may not continue to represent the
tumours from which they were derived. Although both of
these patients were clinically drug resistant, the levels of GSH
and related enzymes in tumour samples and early passage cell
lines derived from them were not particularly high when
compared to the panel of cell lines.
An understanding of clinically relevant resistance
mechanisms in SCLC (as well as other tumour types) could
lead to strategies for circumventing drug resistance. Early
phase clinical trials of agents such as buthionine sulfoximine,
an inhibitor of GSH synthesis (Griffith, 1982), or ethacrynic
acid, an inhibitor of GST, are currently underway (O'Dwyer
et al., 1991; 1992). These agents may prove to be beneficial in
those tumour types in which alterations in GSH metabolism
are clinically important. It appears that ovarian cancer may
fall into this category (Andrews et al., 1985; Ozols et al.,
1987; Mistry et al., 1991), but from the data presented here,
it appears that SCLC does not. It is quite likely that different
tumour types may invoke different cellular protection
mechanisms in response to chemotherapy.
The acquisition of resistance to multiple chemotherapeutic
agents continues to be the major impediment to cure of
SCLC. Despite intensive efforts of many investigators, the
solution to this problem has remained elusive. Evidence from
many laboratories suggests that P-gp is not a major factor.
The data presented here indicate that alterations in GSH
metabolism do not likely play a major role.
Attention should now be directed toward investigating
other potential mechanisms of multidrug resistance in SCLC,
and determining their clinical importance. There is increasing
evidence for involvement of the nuclear enzyme,
topoisomerase II, in multidrug resistance in SCLC (Long et
al., 1986; Zijlstra et al., 1987; de Jong et al., 1990; Binashi et
at., 1990; Minato et at., 1990; Cole et al., 1991; Kasahara et
al., 1992; Giaccone et al., 1992). This enzyme is the int-
ranuclear target of many of the drugs which are part of the
'multidrug resistance phenotype'. However, changes in
topoisomerase II cannot explain the entire problem of drug
resistance in SCLC, since they would not account for resis-
tance to the vinca alkaloids, alkylating agents, or platinum
compounds which do not interact with this DNA unknotting
enzyme. Thus, drug resistance in this disease may be mul-GLUTATHIONE IN SMALL CELL LUNG CANCER 333
tifactorial (Cole, 1992).
Recently, a number of groups have reported changes in
subcellular distribution of drugs in multidrug resistant cell
lines which do not overexpress P-gp (Gervasoni et al., 1991;
Schuurhuis et al., 1991; Marquardt & Center, 1992). These
findings suggest the existence of other transport protein(s)
apart from P-gp, which may act by sequestering drugs away
from their intracellular targets. The recent isolation of a
cDNA encoding a novel ATP-binding cassette transporter
protein which is overexpressed in the H69AR cell line may
shed light on some of these observations (Cole et al., 1992).
Further investigation of the role of this transporter in
clinically acquired drug resistance in SCLC is warranted.
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